San Francisco startup Framework Therapeutics is additionally working on an oral, the moment-each day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Road’s expectations in June whenever a mid-phase examine showed common weight loss of about six% and it strategies to start out An additional mid-phase trial to the top of this calendar